Prenetics Signs Lily Collins as IM8 Global Ambassador and Shareholder
PRE has more than doubled off its 52-week low of $7.175.
Summary
Prenetics signs actress Lily Collins as IM8 Global Ambassador and shareholder, expanding the brand into entertainment and the female consumer market while reaffirming strong revenue guidance and positive free cash flow.
Key Events · M&A and Partnerships · PRE
-
Lily Collins Joins as Global Ambassador
Two-time Golden Globe nominee Lily Collins becomes IM8's first film/television ambassador and a Prenetics shareholder in a multi-year partnership, expanding the brand beyond elite sports into global entertainment.
-
Social Reach and Engagement
Collins brings over 33 million social followers, including 28 million on Instagram, with an engagement rate of approximately 5.9% — several times the 1–2% benchmark for accounts of comparable scale.
-
Targeting Female Consumer Segment
The partnership gives IM8 its most direct route to the female consumer, a stated priority for the brand's next phase of growth, leveraging Collins' multigenerational female audience.
-
Product Pipeline Expansion
IM8 Hydration is set to launch in Q4 2026, with a premium gummies line to follow in the first half of 2027, building on the flagship Daily Ultimate Essentials product.
Analysis · PRE · Life Sciences
Prenetics adds two-time Golden Globe nominee Lily Collins as IM8's first film/television ambassador, expanding the brand's reach beyond elite sports into global entertainment and the female consumer segment. Collins brings over 33 million social followers with an engagement rate several times the benchmark, and takes equity in Prenetics as part of the multi-year deal. The announcement lands alongside raised FY2026 revenue guidance of $220–$230 million and newly initiated FY2027 guidance of $400 million or more, reinforcing IM8's growth trajectory. The company also disclosed positive consolidated Adjusted Free Cash Flow in July 2026, with expectations to remain positive through Q3 2026 and beyond.
At the time of this filing, PRE was trading at $18.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.5M. The 52-week trading range was $7.18 to $23.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.